We are an essay publishing solutions that gives. At all times. You will buy the right author in the united kingdom, put any due date and consider it undertaken. You pay after and only if satisfied custom writing
Biggest generate my essay specialist that helps ensure well timed delivery. Obtain on the internet academic paper service for individuals. By a professional explored Andamp; leading specialized developed duties. Necessary work place for authors write paper for me
The Kansas Coalition for Treatment Access (KCTA) is a group of nearly two-dozen patient advocacy groups fighting for patient protections from insurance companies and to ensure patients have access to treatments their doctors prescribe. You can download our fact sheet here.
KCTA is supporting Senate Bill 93, which was introduced to the Kansas Senate Committee on Public Health and Welfare in February 2019. This legislation would put in place adequate protections against step therapy – an insurance industry practice that can require patients to try, and fail, on lower-cost or older treatments before coverage is granted for what was originally prescribed by the patient’s health care provider.
What will Senate Bill 93 do and NOT do?
- Ensure step therapy protocols are based on widely-accepted clinical guidelines so that medicine – not cost – dictate requirements.
- Create a clear and expeditious process to protect patients from being required to try or stay on a step therapy medication if it is contraindicated or will likely cause an adverse reaction by or physical or mental harm to the patient; if the patient has a relevant comorbid condition.
- Protect patients who have already tried and failed on a drug in their current or previous health plan.
- Protect patients who are currently stable on a drug.
SB93 WILL NOT:
- Will NOT prevent insurance companies from using step therapy nor limit the number of required steps.
- Will NOT require insurers to create new clinical guidelines for step therapy protocols.
- Will NOT prevent insurers from requiring prior authorization before covering a prescription.
- Will NOT prevent insurers from requiring patients to try a generic version of a drug if it is equivalent to the brand-name prescription.
To get in contact with the Coalition, please email Kari Rinker, The National MS Society, email@example.com.